CA
PCVX icon

CoreCap Advisors’s Vaxcyte PCVX Stock Holding History

CoreCap Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465 Hold
8
– – ﹤0.01% 2875
2026
Q1 		$465 Hold
8
– – ﹤0.01% 2662
2025
Q4 		$369 Hold
8
– – ﹤0.01% 2743
2025
Q3 		$288 Hold
8
– – ﹤0.01% 2633
2025
Q2 		$260 Hold
8
– – ﹤0.01% 2592
2025
Q1 		$302 Hold
8
– – ﹤0.01% 2812
2024
Q4 		$655 Buy
+8
New +$794 ﹤0.01% 2445

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CoreCap Advisors's PCVX Position: Q2 2026 in Review

CoreCap Advisors held its Vaxcyte (PCVX) position steady in Q2 2026 at 8 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

CoreCap Advisors first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $655 in Q4 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • CoreCap Advisors held 8 shares of Vaxcyte worth $465 as of Q2 2026.
  • CoreCap Advisors left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2875 holding.
  • CoreCap Advisors first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
  • CoreCap Advisors's Vaxcyte position peaked at $655 in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.